Nasdaq Stockholm Welcomes Xspray Pharma to First North


Stockholm, September 28, 2017 — Nasdaq (Nasdaq: NDAQ) announces that the trading in Xspray Pharma AB’s shares (short name: XSPRAY) commenced today on Nasdaq First North in Stockholm. Xspray Pharma  (“Xspray”) belongs to the health care sector and is the 78th company to be admitted to trading on Nasdaq’s Nordic markets* in 2017.

Founded in 2003, Xspray is a pharmaceutical company specialized in developing improved and generic versions of already marketed drugs. The company employs a patent-protected technology platform to create a pipeline of anti-cancer products with clinically relevant improvements or value enhanced generic versions for patients. Xspray primarily develops so called protein kinase inhibitors (PKI) – the second largest segment within cancer drugs – for targeted cancer treatments. For more information, please visit: www.xspraypharma.com.

“I’m convinced that we can build substantial value for our shareholders over time, as we bring improved and less costly cancer treatments to the market,” said Per Andersson, CEO of Xspray Pharma. “The IPO is a milestone for the company, as it empowers us to meet our goal to bring these new products to the market.”

“We welcome Xspray to Nasdaq First North, where it will make a compelling addition to our health care sector,” said Adam Kostyál, SVP and Head of European listings at Nasdaq. “We congratulate Xspray on its successful listing, and look forward to supporting the company with the investor exposure that comes with a Nasdaq First North listing.”

Xspray Pharma AB has appointed Redeye AB as the Certified Adviser.

*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.

About Nasdaq First North

Nasdaq First North is regulated as a multilateral trading facility, operated by the different exchanges within Nasdaq Nordic (Nasdaq First North Denmark is regulated as an alternative marketplace). It does not have the legal status as an EU-regulated market. Companies at Nasdaq First North are subject to the rules of Nasdaq First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 89 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11 trillion. To learn more, visit: http://business.nasdaq.com

Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS, Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius.

Cautionary Note Regarding Forward-Looking Statements

The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.

Media Relations Contact:
Erik Granström
+46 8 405 78 07
erik.granstrom@nasdaq.com
 

 


Attachments

20170928_XSpray Pharma CEO Per Andersson.jpg